NMTCNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends September 30
NEUROONE MEDICAL TECHNOLOGIES Corp
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.00+0.04 (+4.01%)
Close on Oct 19, 2026
- Market cap
- $8.74M
- P/E (TTM)
- –
- Dividend yield
- –
Neuroone Medical Technologies statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Surgical & Medical Instruments & Apparatus companies for comparison
Valuation
| Measure | Neuroone Medical Technologies | Industry median |
|---|---|---|
| Market Cap | $9.11M | $230.55M |
| Enterprise Value | $7.06M | $202.97M |
| PS Ratio | 0.96 | 3.11 |
| PB Ratio | 2.42 | 3.14 |
| P/TBV Ratio | 2.44 | 4.57 |
Enterprise value
| Measure | Neuroone Medical Technologies | Industry median |
|---|---|---|
| EV / Sales | 0.75 | 2.92 |
Income (trailing twelve months)
| Measure | Neuroone Medical Technologies | Industry median |
|---|---|---|
| Revenue | $9.47M | $102.39M |
| Gross Profit | $5.27M | $60.36M |
| Operating Income | -$7.90M | -$4.31M |
| Pretax Income | -$7.45M | -$2.26M |
| Net Income | -$7.45M | -$6.57M |
| EBITDA | -$7.66M | -$1.98M |
| EPS (Diluted) | -$0.93 | -$0.07 |
Margins
| Measure | Neuroone Medical Technologies | Industry median |
|---|---|---|
| Gross Margin | 55.6% | 55.1% |
| Operating Margin | -83.4% | -6.04% |
| Pretax Margin | -78.6% | -4.11% |
| Profit Margin | -78.6% | -10.5% |
| EBITDA Margin | -80.9% | -2.67% |
| FCF Margin | -75.6% | -0.30% |
Returns
| Measure | Neuroone Medical Technologies | Industry median |
|---|---|---|
| Return on Equity (ROE) | -124.7% | -19.2% |
| Return on Assets (ROA) | -87.6% | -13.3% |
| Return on Invested Capital (ROIC) | -671.9% | -4.11% |
| Return on Capital Employed (ROCE) | -190.6% | -9.07% |
Growth
| Measure | Neuroone Medical Technologies | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 42.8% | 8.85% |
| Revenue Growth (3Y CAGR) | 276.0% | 7.08% |
Balance sheet
| Measure | Neuroone Medical Technologies | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $2.05M | $37.33M |
| Net Cash (Debt) | $2.05M | $3.92M |
| Net Cash Per Share | $0.22 | $0.28 |
| Equity (Book Value) | $3.77M | $57.36M |
| Book Value Per Share | $0.41 | $2.81 |
| Tangible Book Value | $3.74M | $10.71M |
| Working Capital | $3.75M | $54.64M |
Financial position
| Measure | Neuroone Medical Technologies | Industry median |
|---|---|---|
| Current Ratio | 2.84 | 2.50 |
| Quick Ratio | 1.54 | 1.54 |
Cash flow (trailing twelve months)
| Measure | Neuroone Medical Technologies | Industry median |
|---|---|---|
| Operating Cash Flow | -$7.05M | -$653.46K |
| Capital Expenditures | -$109.54K | -$3.69M |
| Free Cash Flow | -$7.16M | -$835.02K |
| FCF Per Share | -$0.79 | -$0.02 |
Efficiency
| Measure | Neuroone Medical Technologies | Industry median |
|---|---|---|
| Asset Turnover | 1.11 | 0.59 |
| Inventory Turnover | 2.01 | 2.21 |
| Revenue Per Employee | $526.04K | $322.57K |
| Profits Per Employee | -$413.64K | -$51.88K |
| Employee Count | 18 | 185 |
Dividends and yields
| Measure | Neuroone Medical Technologies | Industry median |
|---|---|---|
| Earnings Yield | -81.8% | -6.91% |
| FCF Yield | -78.6% | -0.56% |
Shares
| Measure | Neuroone Medical Technologies | Industry median |
|---|---|---|
| Shares Outstanding | 9,105,760 | 44,856,700 |
| Shares Change (YoY) | 45.1% | 3.35% |
| Shares Change (QoQ) | 1.02% | 0.27% |
| Float | 1,329,050 | 37,097,900 |
| Shares Held by Insiders | 85.4% | 10.6% |
| Shares Held by Institutions | 22.7% | 63.5% |
Scores
| Measure | Neuroone Medical Technologies | Industry median |
|---|---|---|
| Altman Z-Score | -18.81 | 1.95 |
| Piotroski F-Score | 6 | 5 |
| Beneish M-Score | 0.01 | -2.64 |
Calculated by StockData from Neuroone Medical Technologies's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.